دورية أكاديمية
أعرض في EDS

The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.

التفاصيل البيبلوغرافية
العنوان: The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.
المؤلفون: Marcovecchio ML; Department of Paediatrics, University of Cambridge, Cambridge, UK. mlm45@medschl.cam.ac.uk.; Department of Paediatric Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. mlm45@medschl.cam.ac.uk., Hendriks AEJ; Department of Paediatrics, University of Cambridge, Cambridge, UK.; Department of Paediatric Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Delfin C; Department of Pharmacometrics, Novo Nordisk A/S, Søborg, Denmark., Battelino T; Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Danne T; Centre for Paediatric Endocrinology, Diabetology, and Clinical Research, Auf Der Bult Children's Hospital, Hannover, Germany., Evans ML; Wellcome MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Johannesen J; Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Paediatrics, Copenhagen University Hospital, Herlev, Denmark; Institute of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark., Kaur S; Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Paediatrics, Copenhagen University Hospital, Herlev, Denmark; Institute of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark., Knip M; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Pediatric Research Center, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland., Overbergh L; Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium., Pociot F; Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Paediatrics, Copenhagen University Hospital, Herlev, Denmark; Institute of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark., Todd JA; Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Van der Schueren B; Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium., Wicker LS; Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Peakman M; Immunology & Inflammation Research Therapeutic Area, Sanofi, MA, USA., Mathieu C; Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
مؤلفون مشاركون: INNODIA consortium
المصدر: Diabetologia [Diabetologia] 2024 Jun; Vol. 67 (6), pp. 995-1008. Date of Electronic Publication: 2024 Mar 22.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0428 (Electronic) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin Springer Verlag
مواضيع طبية MeSH: Diabetes Mellitus, Type 1*/diagnosis , Diabetes Mellitus, Type 1*/blood , Diabetes Mellitus, Type 1*/epidemiology , C-Peptide*/blood , Autoantibodies*/blood , Glycated Hemoglobin*/metabolism, Humans ; Adolescent ; Child ; Male ; Female ; Adult ; Young Adult ; Child, Preschool ; Blood Glucose/metabolism ; Cohort Studies ; Infant ; Europe/epidemiology ; Middle Aged ; Insulin-Secreting Cells/metabolism
مستخلص: Aims/hypothesis: Type 1 diabetes is an heterogenous condition. Characterising factors explaining differences in an individual's clinical course and treatment response will have important clinical and research implications. Our aim was to explore type 1 diabetes heterogeneity, as assessed by clinical characteristics, autoantibodies, beta cell function and glycaemic outcomes, during the first 12 months from diagnosis, and how it relates to age at diagnosis.
Methods: Data were collected from the large INNODIA cohort of individuals (aged 1.0-45.0 years) newly diagnosed with type 1 diabetes, followed 3 monthly, to assess clinical characteristics, C-peptide, HbA 1c and diabetes-associated antibodies, and their changes, during the first 12 months from diagnosis, across three age groups: <10 years; 10-17 years; and ≥18 years.
Results: The study population included 649 individuals (57.3% male; age 12.1±8.3 years), 96.9% of whom were positive for one or more diabetes-related antibodies. Baseline (IQR) fasting C-peptide was 242.0 (139.0-382.0) pmol/l (AUC 749.3 [466.2-1106.1] pmol/l × min), with levels increasing with age (p<0.001). Over time, C-peptide remained lower in participants aged <10 years but it declined in all age groups. In parallel, glucose levels progressively increased. Lower baseline fasting C-peptide, BMI SD score and presence of diabetic ketoacidosis at diagnosis were associated with lower stimulated C-peptide over time. HbA 1c decreased during the first 3 months (p<0.001), whereas insulin requirement increased from 3 months post diagnosis (p<0.001).
Conclusions/interpretation: In this large cohort with newly diagnosed type 1 diabetes, we identified age-related differences in clinical and biochemical variables. Of note, C-peptide was lower in younger children but there were no main age differences in its rate of decline.
(© 2024. The Author(s).)
References: Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74. (PMID: 30528100)
Diabetes. 2022 Jul 1;71(7):1591-1596. (PMID: 35499624)
Diabetes Care. 2022 Apr 1;45(4):871-879. (PMID: 35147706)
Lancet Diabetes Endocrinol. 2023 Apr;11(4):251-260. (PMID: 36958868)
Diabetologia. 2020 Jun;63(6):1258-1267. (PMID: 32172310)
Lancet Diabetes Endocrinol. 2021 Oct;9(10):671-680. (PMID: 34481558)
Diabetes Care. 2013 Nov;36(11):3454-9. (PMID: 23990516)
Diabetes Care. 2013 Dec;36(12):4030-5. (PMID: 24130350)
Diabetes Metab Res Rev. 2013 Jan;29(1):85-9. (PMID: 23081842)
Pediatr Diabetes. 2022 Dec;23(8):1270-1276. (PMID: 36537523)
PLoS One. 2013 Jun 06;8(6):e64683. (PMID: 23762245)
Diabetes Care. 2016 Oct;39(10):1664-70. (PMID: 27422577)
Diabetes. 2008 Nov;57(11):3152-5. (PMID: 18694972)
Diabetes. 2014 Feb;63(2):739-48. (PMID: 24089509)
Diabetes Care. 2009 Oct;32(10):1839-44. (PMID: 19587365)
Diabetes. 2014 Nov;63(11):3835-45. (PMID: 24939426)
Diabetes Res Clin Pract. 2021 May;175:108838. (PMID: 33901625)
Diabetologia. 2001 Jan;44(1):3-15. (PMID: 11206408)
Pediatr Diabetes. 2010 Jun;11(4):218-26. (PMID: 19708904)
Trials. 2022 May 18;23(1):414. (PMID: 35585600)
Diabetes. 2012 Aug;61(8):2066-73. (PMID: 22688329)
Diabetes Care. 2010 Jun;33(6):1206-12. (PMID: 20508230)
Diabetologia. 2003 Mar;46(3):420-5. (PMID: 12687342)
Eur J Clin Nutr. 1990 Jan;44(1):45-60. (PMID: 2354692)
JAMA Pediatr. 2022 Dec 1;176(12):1248-1259. (PMID: 36215053)
Front Med (Lausanne). 2022 Jul 12;9:932086. (PMID: 35903316)
Lancet Diabetes Endocrinol. 2022 Nov;10(11):763-765. (PMID: 36202117)
Diabetologia. 2012 Dec;55(12):3359-68. (PMID: 22990715)
Diabetes Care. 2015 Mar;38(3):476-81. (PMID: 25519448)
Diabetes Res Clin Pract. 2013 May;100(2):203-9. (PMID: 23529064)
Lancet Diabetes Endocrinol. 2022 Nov;10(11):786-794. (PMID: 36202118)
Diabetes. 2022 Apr 1;71(4):610-623. (PMID: 35316839)
Nat Rev Endocrinol. 2023 Sep;19(9):542-554. (PMID: 37337007)
Horm Res. 2002;58 Suppl 1:66-71. (PMID: 12373017)
Diabetes Care. 2023 Jan 1;46(Suppl 1):S19-S40. (PMID: 36507649)
Diabet Med. 2021 Dec;38(12):e14712. (PMID: 34614253)
Diabetes Care. 2008 Jul;31(7):1392-6. (PMID: 18356404)
Diabetes. 2023 Sep 1;72(9):1289-1296. (PMID: 37368990)
Diabetes Care. 2020 Jan;43(1):5-12. (PMID: 31753960)
Lancet Diabetes Endocrinol. 2023 Jul;11(7):465-473. (PMID: 37290465)
Diabetes Care. 2009 Aug;32(8):1384-90. (PMID: 19435955)
Diabetes Care. 2018 Jul;41(7):1486-1492. (PMID: 29880650)
Diabetes Care. 2020 Jan;43(1):169-177. (PMID: 31558544)
Lancet. 2023 Jun 24;401(10394):2149-2162. (PMID: 37030316)
JAMA Netw Open. 2023 Jun 1;6(6):e2321281. (PMID: 37389869)
Clin Exp Immunol. 2022 Dec 15;210(2):151-162. (PMID: 36181724)
معلومات مُعتمدة: 115797 Innovative Medicines Initiative
فهرسة مساهمة: Keywords: Age; Beta cell function; C-peptide; Prevention; Subgroups; Treatment; Type 1 diabetes
المشرفين على المادة: 0 (C-Peptide)
0 (Autoantibodies)
0 (Glycated Hemoglobin)
0 (Blood Glucose)
تواريخ الأحداث: Date Created: 20240322 Date Completed: 20240429 Latest Revision: 20240502
رمز التحديث: 20240502
مُعرف محوري في PubMed: PMC11058619
DOI: 10.1007/s00125-024-06124-5
PMID: 38517484
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0428
DOI:10.1007/s00125-024-06124-5